The Supreme Court Rekindles the Reflectors on Bayer
Bayer returns to the market after the US Supreme Court has decided to examine its claim in the Roundup case, a move that could reduce thousands of cases related to the alleged carcinogenic risk of the throwaway. The news has rekindled the optimism of investors, pushing the title to the maximum of recent years and feeding a key question: the long downward market started after the acquisition of Monsanto in 2018 has finally reached the end of the line? With a decision expected by the summer, the Court's verdict could represent the final turning point for the German group, both legally and financially.
In recent years Bayer has been at the centre of one of the most complex and expensive legal disputes in its history: the dispute related to RoundupTM, the herbicide based on the countervailable acquired in 2018 with the 63 billion dollar transaction that led Monsanto under the control of the German group. Today, between interventions of the Supreme Court of the United States and new billionaire agreements, the story seems to be moving towards a decisive phase, with important financial and stock exchange repercussions.
Bayer shares have been strongly raised on several recent occasions, supported by both judicial developments and announcements of transactive agreements. In particular, the title has jumped by more than 12% in European negotiations after the administration of President Donald Trump has urged the Supreme Court of the United States to examine the company's request to limit thousands of legal cases. In a memorandum filed at the Court, Solicitor General D. John Sauer supported Bayer's position that the Federal Pesticide Law prevails over state labelling laws.
According to this defensive line, once the Environmental Protection Agency (EPA) approves a label
The Durnell case and the Over 67,000 Pendants
The case is the case of John Durnell, who was diagnosed with non-Hodgkin's lymphoma after prolonged exposure to the herbicide. A Missouri court confirmed a $1.25 million compensation, and Bayer asked federal judges to review the decision. Currently, the company is facing over 67,000 similar cases at national level. The plaintiffs claim that they have developed cancer due to domestic or professional use of the product; Bayer replies that decades of scientific research demonstrate its safety.
In parallel to the judicial strategy, the group introduced a comprehensive multi-faceted transactive strategy. Bayer announced a US$10.5 billion overall plan to resolve current and future causes related to cancer from Roundup. Of these, $7.5 billion (later defined to a maximum of $7.25 billion in official communication) are destined to a national collective agreement in the United States, aimed at covering both the already pending causes and potential claims that might arise in the next 20 years. To this is added about $3 billion for separate agreements related to existing causes.
The new collective agreement, presented at the Tribunal of the Circuit of St. Louis, Missouri, introduces a long-term claim management programme, up to 21 years, with decreasing annual payments and maximum ceiling. Compared to a proposal of 2020, limited to four years and based on a scientific panel for future disputes, the new scheme provides for increased financing and centralised management by a professional manager of claims. The agreement covers subjects exposed to Roundup before 17 February 2026 who have already received a diagnosis of non-Hodgkin lymphoma or receive it within 16 years of final approval. It remains subject to the approval of the court and the class members may choose not to join.
The CEO Bill Anderson stressed that the collective agreement and the case before the Supreme Court are . On the one hand, the transaction offers a path to reduce legal uncertainty; on the other, a favourable ruling of the Supreme Court could largely prevent future requests based on alleged omissions of warnings under state law.
Financial Impact, Provisions, Debt and Cash Flows
From a financial point of view, the impact is significant. Bayer has already paid around 10 billion dollars to close most of the cases until 2020, but new legal actions have continued to accumulate. With the latest resolutions, the provisions and the total liabilities for the litigation will rise from 7,8 billion euros (of which 6,5 billion are related to the countervailable) to 11,8 billion euros (9,6 billion related to the countervailable). For 2026 there is a total disbursement for the litigation of about 5 billion euros, with consequent negative free cash flow. The immediate financing will be covered by a banking credit line of 8 billion dollars, while the definitive financing will take place through the issuance of senior bonds and hybrid instruments recognized as capital by the rating agencies, without resorting to an increase in capital.
Analysts welcomed developments. Chris Counihan of Jefferies defined the deposit at the Supreme Court as a positive step forwards
Bayer reiterates that the agreements do not involve any admission of liability. The main global regulatory authorities, including the US EPA and the European Union authorities, continue to believe that herbicides based on the herbicides can be used safely and are not carcinogenic. The company also stresses that regulatory uncertainty could undermine the availability of essential agricultural innovations for farmers and the food system.
Meanwhile, investors' interest remains high. Quantitative analysis tools such as ProPicks AI include Bayer among the companies monitored through over one hundred financial metrics, assessing fundamental, momentum and risk-performance ratio. However, the real determining variable for the title remains the outcome of the comparison before the Supreme Court and the actual approval and implementation of the collective agreement.
Beyond Roundup, Financial Stability and Industrial Mission
For a group that in 2024 recorded 46.6 billion euros of turnover, employs approximately 93,000 employees and invests over 6 billion euros per year in research and development, the final closure of the Roundup chapter represents much more than a legal issue: it is an essential condition to restore financial stability, fully recover the confidence of the markets and return to focus on its declared mission, \ Health for all, Hunger for no one \ .